Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results